COVID-19 Research at Elettra
Projects
Elettra is partner of EXSCALATE4Cov (E4C), a public-private consortium supported by the European Commission’s Horizon 2020 tender for projects to counter the Coronavirus pandemic. The E4C consortium is composed by 18 institutions from 7 European countries coordinated by Dompé Farmaceutici. The aim of E4C is twofold: to identify molecules capable of targeting the coronavirus (2019-nCoV) and to develop an effective tool for countering future pandemics to be consolidated over time.
The project is leveraging EU’s supercomputing resources coupling them with some of the continent’s best life-science research labs to counter international pandemics faster and more efficiently.
Elettra contributes to E4C by determining the crystallographic structure of some of the SARS-Cov-2 druggable proteins in complex with selected hit compounds. The activities encompass the production and crystallization of the recombinant viral proteins, by the Elettra Protein facility and by the diffraction data collection and reduction by XRD1 and XRD2 beamlines.
Publications
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02344-6
Participation in international joint initiatives
Elettra is member of the LEAPS Consortium,
SR20 Summit on COVID-19
Elettra was among the Participating organizations of the SR20 Summit on COVID-19